Revakinagene for MacTel: Is the Benefit Worth the Cost? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Revakinagene for MacTel: Is the Benefit Worth the Cost?

High-cost therapies have consistently been approved for conditions with significant unmet medical need, particularly when irreversible loss of function, such as blindness, is imminent. Decisions are based not only on clinical efficacy but also on prevention of long-term societal costs and preservation of patient autonomy. Therefore, it is our opinion that the benefit of revakinagene is worth the premium cost.

  • By

  • Michael Colucciello, MD

  • Martin Friedlander, MD, PhD

  • Kristin Raming, MD

  • September 1, 2026

  • 15 min

Share

  • 1

    Macular telangiectasia type 2 (MacTel) is a rare neurodegenerative condition with a prevalence of 0.045% to 0.1%.

  • 2

    Revakinagene, an encapsulated cell therapy, is the first FDA-approved treatment for MacTel, reducing photoreceptor loss by 55% at 24 months.

  • 3

    Serious adverse events occurred in 5% of patients treated with revakinagene, primarily related to the surgical procedure.

  • 4

    The cost of revakinagene is approximately $250,000, which raises questions about its value compared to other gene therapies.

  • 5

    The discordance between structural preservation and visual function in MacTel complicates the estimation of quality-adjusted life-year gains.

Original Source(s)

Revakinagene for MacTel: Is the Benefit Worth the Cost?

  • by Michael Colucciello, MD, Martin Friedlander, MD, PhD, Kristin Raming, MD

  • September 1, 2026

Related Content

Chinese Trial Validates Scleral Lenses

Large Chinese trial confirms strong visual outcomes with four-zone scleral lenses for irregular corneas

  • August 28, 2026

  • 3 min
Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

The Scleral Lens Vault: <br>Observing Your Fluorescein</br>

In the times of ever-advancing new technology for precise fitting of scleral lenses, has the art of diagnostic fitting fallen to the wayside